• Provision of signed and dated informed consent and HIPAA form

• Male subjects 18 years of age and older

• Known primary prostate cancer and Grade Group 3 to 5 (≥ cT3) or one or more of the following:

‣ Suspected extraprostatic disease (EPD) (extracapsular extension (ECE) and/or seminal vesicle infiltration (SVI)),

⁃ 3 or more biopsy cores of grade group 3-5;

⁃ Suspected lymph node metastasis (clinical stage cN1, or by magnetic resonance imaging (mriN+), or by Prostate Specific Membrane Antigen positron emission tomography (PSMA PET+));

• Planned to undergo a standard of care robotic prostatectomy and lymph node dissection

• Ability to understand the requirements of the study and agree to abide by the study restrictions and to return for the required assessments

• Agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including through final study visit (6 weeks) after the dose of study drug. Sperm donation is prohibited during the study and for 3 months after the dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.